← Eichor
Study identifier: NCT07029906 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure

Condition: Side-Effect · Heart Failure  ·  Sponsor: Imperial College London

PhaseNA
Planned participants150
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Beta-blocker tablets are an effective treatment for heart failure that make people live longer and reduce the need to be admitted to hospital. Many patients who are at high risk of death are prescribed beta-blockers, but later choose to stop taking them because of symptoms that they perceive to be side-effects. Some patients' symptoms may genuinely be side-effects due to the beta-blocker tablets, but, in reality, many of the symptoms which may lead to people stopping beta-blockers are actually experienced at similar rates compared to placebo. The symptoms may be caused by heart failure itself, or the expectation that they will have a side effect when they take a tablet (the nocebo effect). There is a need to be able to identify the majority of patients who aren't actually having side-effects so that they can restart beta-blockers and not miss out on life-prolonging treatment. To answer this question reliably and with high precision requires a personalised approach with an 'N-of-1' study. This study will measure participants' symptoms in three scenarios: taking a beta-blocker tablet (bisoprolol 2.5mg) or a placebo tablet or no study medication in a randomised order. The primary aim of this study is to determine, for an individual, whether the adverse effects of beta-blockade in heart failure are genuine. Specifically, the objectives are: 1. To determine the proportion of a patient's symptoms that are due to taking beta-blocker tablets, and the proportion that are due to the …

This description comes directly from the study's public registry record.

Talk to the study team

Sameer Zaman, MBBS  ·  020 3313 1000  ·  sameer.zaman1@nhs.net

Amanpal Sidhu, MBChB  ·  020 3313 1000  ·  asidhu@ic.ac.uk

Always discuss trial participation with your own doctor first.

Locations (1)

Imperial College LondonLondon, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07029906